ICPerMed conference


Erik de Vrieze

Department of Otorhinolaryngology, Radboud University Medical Center, Netherlands


Erik de Vrieze performed his doctoral studies at the department of Animal Physiology at the Radboud University (Nijmegen, the Netherlands). In this research, he developed a model for medium-throughput screening of anti-osteoporosis drug based on the scales of transgenic zebrafish. His love for zebrafish models, and desire to work in closer contact with patients, inspired his move to the department of Otorhinolaryngology at the Radboud University Medical Center (Nijmegen, the Netherlands). Here, Erik de Vrieze is a core member part of the NFU-accredited “Hearing & Genes” National Centre of Expertise. Together with his colleagues, he invested in unique and close collaborations between patients and academia. His current research is aimed at elucidating the pathophysiology of Usher syndrome (deafblindness) and inherited hearing loss, and to develop needed novel (genetic) treatments for these disorders. He contributed to the proof-of-concept studies of antisense oligonucleotide (ASO)-based exon-skipping therapy for USH2A-associated retinal degeneration (PMID: 33895329), which form the scientific basis of the successful clinical trial “STELLAR” (NCT03780257, ProQR Therapeutics). Based on this success, initiated the development of ASO-based treatments for dominantly-inherited hearing loss. He has obtained several